Literature DB >> 21768937

Buprenorphine: the basic pharmacology revisited.

Alan Cowan1.   

Abstract

The historical background leading to the current use of buprenorphine as an analgesic and its role in the management of opioid dependence is summarized. The popular description of buprenorphine as a "partial agonist" is discussed in relation to efficacy in animal models of antinociception and clinical analgesia. The latest information on the respiratory depressant effects of buprenorphine and its N-dealkylated metabolite (norbuprenorphine) is presented. New data on the buprenorphine withdrawal syndrome in rats are described.

Entities:  

Year:  2007        PMID： 21768937     DOI： 10.1097/ADM.0b013e31806c9202

Source DB:  PubMed          Journal:  J Addict Med        ISSN： 1932-0620            Impact factor:   3.702


  19 in total

1.  Using a Learning Collaborative Strategy With Office-based Practices to Increase Access and Improve Quality of Care for Patients With Opioid Use Disorders.

Authors:  Benjamin R Nordstrom; Elizabeth C Saunders; Bethany McLeman; Andrea Meier; Haiyi Xie; Chantal Lambert-Harris; Beth Tanzman; John Brooklyn; Gregory King; Nels Kloster; Clifton Frederick Lord; William Roberts; Mark P McGovern
Journal:  J Addict Med       Date:  2016 Mar-Apr       Impact factor: 3.702

Review 2.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

3.  Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.

Authors:  T Garimella; R Wang; W-L Luo; P Wastall; H Kandoussi; M DeMicco; R D Bruce; C Hwang; R Bertz; M Bifano
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

4.  P-gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine.

Authors:  Michael Z Liao; Chunying Gao; Laura M Shireman; Brian Phillips; Linda J Risler; Naveen K Neradugomma; Prachi Choudhari; Bhagwat Prasad; Danny D Shen; Qingcheng Mao
Journal:  Pharmacol Res       Date:  2017-01-19       Impact factor: 7.658

Review 5.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

6.  Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors.

Authors:  Edgardo Falcon; Caroline A Browne; Rosa M Leon; Vanessa C Fleites; Rachel Sweeney; Lynn G Kirby; Irwin Lucki
Journal:  Neuropsychopharmacology       Date:  2016-03-16       Impact factor: 7.853

7.  Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice.

Authors:  Edgardo Falcon; Kaitlyn Maier; Shivon A Robinson; Tiffany E Hill-Smith; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2014-09-03       Impact factor: 4.530

8.  Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.

Authors:  Kirsten E Smith; Martha D Tillson; Michele Staton; Erin M Winston
Journal:  Drug Alcohol Depend       Date:  2020-01-09       Impact factor: 4.492

9.  Pharmacokinetics of buprenorphine following intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta).

Authors:  K R Kelly; B H Pypendop; K L Christe
Journal:  J Vet Pharmacol Ther       Date:  2014-03-25       Impact factor: 1.786

10.  Illicit opioid intoxication: diagnosis and treatment.

Authors:  A Fareed; S Stout; J Casarella; S Vayalapalli; J Cox; K Drexler
Journal:  Subst Abuse       Date:  2011-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.